Boca Raton, Florida and Somerset, New Jersey. October 2026

LGM Pharma has acquired Sannova Analytical

Sannova continues under its own name, led by its current management team. Combined, the clients working with both companies gain access to: active pharmaceutical ingredient (API) sourcing, regulatory and market intelligence, and a combined analytical platform that covers a molecule from characterization through commercialization.

The Somerset laboratory, by the record

3,500+

Current good manufacturing practice (cGMP) analytical studies completed

1,500+

Good Laboratory Practice (GLP) bioanalytical studies completed

20

Years in business, founded in 2006

21,000

Square foot facility with 14 LC-MS/MS systems

What this changes for you, and what it does not

Logo for Sannova Analytical featuring a stylized “SA” icon with a red circle inside a yellow-to-orange circular arc.

If you are currently working with Sannova

LGM Pharma

If you are currently working with LGM Pharma

cGMP Analytical Testing

Trace impurity identification specialists with a full release and stability laboratory

Sannova Analytical has completed more than 3,500 cGMP analytical studies for pharmaceutical, generic, and contract manufacturers, specializing in high-sensitivity impurity assays.

Nitrosamines and NDSRIs

Extractables and leachables

Elemental impurities testing

Method development and validation

Release and stability testing

Where the samples go

GLP Bioanalytical Testing

Preclinical to clinical Phase 4. Small molecules, proteins, peptides, oligonucleotides, and biologics.

Sannova has completed more than 1,500 GLP studies supporting pharmacokinetic (PK), toxicokinetic (TK), and immunogenicity programs, with methods validated to ICH M10. One team carries your method from the first animal study through clinical, so it never changes hands between laboratories. The scientists who develop our assay in preclinical studies are the scientists who run it from Phase 1 to Phase 4.

PK, TK, and DMPK

Immunogenicity and ADA

Ligand binding assays

ICH M10 method development and validation

Nanoparticles and metalloproteins

Cell and gene therapy assays

One partner, from the API to the clinical sample

LGM PHARMA

API Sourcing

Procurement from a global network of qualified API partners, with regulatory and market intelligence behind the selection.

LGM PHARMA AND SANNOVA

Release and stability

Method development and validation, impurity work, and release and stability testing of APIs and drug products, clinical through commercial.

SANNOVA ANALYTICAL

Bioanalysis

Drug and metabolite quanititation in biological matrices supporting PK, TK, bioequivalence, and immunogenicity programs.

“Sannova gives us a U.S. based team that develops and validates its methods at the center of the Northeast pharmacautical corridor. This acquisition provides additional capabilities, but also adds capacity for the growing volume of work our clients are bringing to us.ˮ

Prasad Raje, Ph.D.

Chief Executive Officer, LGM Pharma

“Our clients chose Sannova for the people and methods behind their data, and those stay in place. LGM Pharmaʼs backing lets us continue investing in our scientists, instruments, capacity, and client services faster than we could independently.ˮ

Malleswar Kollu

President and Chief Executive Officer, Sannova Analytical

Read the capability flyer

Two pages on what the Somerset laboratory runs, the standards each service is validated to, and the instruments behind it. Open it here or download the PDF.

Sannova Analytical logo and text reading “cGMP Analytical Testing” and “Trace impurity identification specialists with a full release and stability laboratory,” alongside a scientist working in a lab.

cGMP Analytical Testing

Nitrosamines and NDSRIs, extractables and leachables, elemental impurities, method development and validation, and release and stability testing, with the USP and ICH standards each is validated to.

A scientist in a lab coat works at a fume hood, next to the Sannova Analytical logo and text describing their GLP bioanalytical testing services.

GLP Bioanalytical Testing

PK, TK, and DMPK, immunogenicity and ADA, ligand binding, nanoparticles and metalloproteins, and cell and gene therapy assays, validated to ICH M10 from preclinical through Phase 4.

Announcement that LGM Pharma has acquired Sannova Analytical, noting that Sannova will continue operations under its own name in Somerset, NJ.